MA51223A - Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine - Google Patents

Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine

Info

Publication number
MA51223A
MA51223A MA051223A MA51223A MA51223A MA 51223 A MA51223 A MA 51223A MA 051223 A MA051223 A MA 051223A MA 51223 A MA51223 A MA 51223A MA 51223 A MA51223 A MA 51223A
Authority
MA
Morocco
Prior art keywords
monoclonal antibody
antibody against
lyophilized formulation
transthyretin
against transthyretin
Prior art date
Application number
MA051223A
Other languages
English (en)
Inventor
Andrea Hawe
Stefan Heindl
Jay Soto
Ruedeeporn Tantipolphan
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MA51223A publication Critical patent/MA51223A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA051223A 2017-11-29 2018-11-28 Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine MA51223A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762592294P 2017-11-29 2017-11-29

Publications (1)

Publication Number Publication Date
MA51223A true MA51223A (fr) 2020-10-07

Family

ID=66665773

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051223A MA51223A (fr) 2017-11-29 2018-11-28 Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine

Country Status (18)

Country Link
US (1) US11873332B2 (fr)
EP (1) EP3717512A4 (fr)
JP (1) JP7337057B2 (fr)
KR (1) KR20200090164A (fr)
CN (1) CN111433223A (fr)
AU (1) AU2018375356A1 (fr)
BR (1) BR112020010483A2 (fr)
CA (1) CA3083356A1 (fr)
CL (1) CL2020001391A1 (fr)
CU (1) CU20200042A7 (fr)
EA (1) EA202091130A1 (fr)
IL (1) IL274958A (fr)
JO (1) JOP20200132A1 (fr)
MA (1) MA51223A (fr)
MX (1) MX2020005433A (fr)
PE (1) PE20211453A1 (fr)
SG (1) SG11202004187UA (fr)
WO (1) WO2019108689A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2019071205A1 (fr) 2017-10-06 2019-04-11 Prothena Biosciences Limited Anticorps anti-transthyrétine
EP3717512A4 (fr) 2017-11-29 2021-08-25 Prothena Biosciences Limited Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
KR20230009950A (ko) 2020-05-12 2023-01-17 뉴리뮨 아게 Ttr 아밀로이드증에 대한 조합 치료법
CN113845593B (zh) * 2021-10-27 2023-03-10 福州迈新生物技术开发有限公司 抗α-SMA蛋白单克隆抗体、细胞系及其应用
WO2023099788A1 (fr) 2021-12-03 2023-06-08 Neurimmune Ag Nouveau dosage de puissance pour des médicaments à base d'anticorps et moyens utiles associés
WO2024105092A1 (fr) 2022-11-15 2024-05-23 Neurimmune Ag Compositions pharmaceutiques pour le traitement ou la prévention de l'amylose médiée par la transthyrétine
WO2024105062A1 (fr) 2022-11-15 2024-05-23 Neurimmune Ag Méthodes de traitement ou de prévention de l'amylose médiée par la transthyrétine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7485616B2 (en) 2000-04-05 2009-02-03 University Of Tennessee Research Foundation Methods of investigating, diagnosing, and treating amyloidosis
US9535076B2 (en) 2002-09-12 2017-01-03 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
WO2010012004A2 (fr) 2008-07-25 2010-01-28 The Regents Of The University Of California Anticorps monoclonaux spécifiques d'agrégats amyloïdes pathologiques communs aux amyloïdes formés à partir de protéines ayant des séquences différentes
DE60336848D1 (de) 2002-09-12 2011-06-01 Univ California Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
US20110200609A1 (en) 2002-09-12 2011-08-18 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
WO2005025516A2 (fr) 2003-09-12 2005-03-24 The Regents Of The University Of California Anticorps monoclonaux specifiques a des intermediaires d'agregation de poids moleculaire eleve communs a des amyloides formes a partir de proteines de sequence differente
CA2604423A1 (fr) 2005-04-13 2006-10-19 Garvan Institute Of Medical Research Animal modifie depourvu du gene pyy fonctionnel, anticorps monoclonaux fixant les isoformes pyy et leurs utilisation
WO2007098607A1 (fr) 2006-03-03 2007-09-07 Amorfix Life Sciences Ltd. Méthodes et compositions visant à traiter et à détecter des maladies induites par une sod1 à repliement incorrect
WO2008005455A2 (fr) 2006-07-03 2008-01-10 The Johns Hopkins University Déplétion des peptides par anticorps et son application à la préparation des échantillons pour spectrométrie de masse
EP2078189B1 (fr) 2006-10-20 2012-10-10 Clondiag GmbH Dispositifs et méthodes de dosage destinés à la détection de substances à analyser
WO2010030203A1 (fr) 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Anticorps monoclonal dirigé contre la transthyrétine humaine amyloïdogène et des formes modifiées de celle-ci et son utilisation dans la détection et le traitement de la fap et de pathologies présentant une ttr modifiée
JP5898495B2 (ja) 2008-10-06 2016-04-06 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア ミスフォールドタンパク質エピトープを予測するための方法およびシステム
JP2010195710A (ja) 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用
US20120107321A1 (en) 2009-03-02 2012-05-03 The University Of British Columbia Antibodies And Epitopes Specific To Misfolded Prion Protein
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
FI20115165A0 (fi) 2011-02-21 2011-02-21 Polysackaridforskning I Uppsala Ab Terapeuttisia ja diagnostisia menetelmiä
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2857419B1 (fr) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison d'antigène supprimant un antigène associé
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US9534048B2 (en) 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
WO2014142334A1 (fr) 2013-03-12 2014-09-18 国立大学法人名古屋大学 Procédé pour accroître une photosynthèse et un rendement de plantes
US20160168235A1 (en) 2013-07-19 2016-06-16 Board Of Regents Of The University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies
WO2015092077A1 (fr) 2013-12-20 2015-06-25 Neurimmune Holding Ag Thérapie de l'amyloïdose de la transthyrétine (ttr) à base d'anticorps, et anticorps d'origine humaine afférents
JP6818268B2 (ja) 2014-01-29 2021-01-20 Ｋｍバイオロジクス株式会社 抗トランスサイレチンヒト化抗体
EP3981874A1 (fr) 2014-01-29 2022-04-13 KM Biologics Co., Ltd. Anticorps humain anti-transthyrétine
JP6672270B2 (ja) 2014-08-29 2020-03-25 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トランスサイレチン（ｔｔｒ）媒介アミロイドーシスの治療方法
TWI705827B (zh) * 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
TWI711631B (zh) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI718122B (zh) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3478715A2 (fr) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anticorps anti-transthyrétine
JP7076711B2 (ja) 2016-07-02 2022-05-30 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
BR112020006791A2 (pt) 2017-10-06 2020-12-01 Prothena Biosciences Limited métodos de detecção de transtirretina
WO2019071205A1 (fr) 2017-10-06 2019-04-11 Prothena Biosciences Limited Anticorps anti-transthyrétine
EP3717512A4 (fr) 2017-11-29 2021-08-25 Prothena Biosciences Limited Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine
WO2021168156A1 (fr) 2020-02-20 2021-08-26 Prothena Biosciences Limited Surveillance de l'amyloïdose de la transthyrétine

Also Published As

Publication number Publication date
IL274958A (en) 2020-07-30
PE20211453A1 (es) 2021-08-05
EA202091130A1 (ru) 2020-08-28
MX2020005433A (es) 2020-08-27
CU20200042A7 (es) 2021-03-11
JOP20200132A1 (ar) 2022-10-30
US20200362023A1 (en) 2020-11-19
CN111433223A (zh) 2020-07-17
CL2020001391A1 (es) 2020-11-13
JP2021504372A (ja) 2021-02-15
CA3083356A1 (fr) 2019-06-06
KR20200090164A (ko) 2020-07-28
AU2018375356A1 (en) 2020-05-14
EP3717512A1 (fr) 2020-10-07
EP3717512A4 (fr) 2021-08-25
BR112020010483A2 (pt) 2020-10-20
JP7337057B2 (ja) 2023-09-01
US11873332B2 (en) 2024-01-16
SG11202004187UA (en) 2020-06-29
WO2019108689A1 (fr) 2019-06-06

Similar Documents

Publication Publication Date Title
MA51223A (fr) Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine
MA49043A (fr) Formulation stable d'anticorps
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA53434A (fr) Anticorps anti-tigit
MA52884A (fr) Anticorps anti-il-11
MA47268A (fr) Anticorps anti-gpc3
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA45784A (fr) Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
MA49749A (fr) Anticorps anti-cd137
MA52212A (fr) Anticorps multivalent
MA45231A (fr) Anticorps anti-ige
MA51903A (fr) Formulations d'anticorps b7-h4
MA52366A (fr) Anticorps anti-tl1a optimisés
MA52152A (fr) Anticorps
MA44054A (fr) Plateforme d'anticorps bispécifique
MA54052A (fr) Formulation d'anticorps
MA51134A (fr) Anticorps anti-alpha-synucléine
MA44236A (fr) Anticorps anti-tgfbêta 2
MA54139A (fr) Formulation d'anticorps
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées